Sanders Morris Harris LLC Erasca, Inc. Transaction History

Sanders Morris Harris LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$1.67 - $2.55 $940,525 - $1.44 Million	-563,189 Reduced 97.91%	12,000 $24,000
Q4 2023 Jan 10, 2024	BUY	$1.67 - $2.49 $250,319 - $373,231	149,892 Added 35.24%	575,189 $1.23 Million
Q3 2023 Oct 13, 2023	BUY	$1.97 - $2.91 $837,835 - $1.24 Million	425,297 New	425,297 $837,000
Q2 2022 Jul 11, 2022	SELL	$4.58 - $8.72 $61,532 - $117,153	-13,435 Closed	0 $0
Q1 2022 Apr 11, 2022	BUY	$8.6 - $15.48 $115,541 - $207,973	13,435 New	13,435 $116,000

141

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $333M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Sanders Morris Harris LLC, based on Form 13F filings with the SEC.

Stay updated on Sanders Morris Harris LLC with notifications on news.